ML-299 is a dual inhibitor of the two mammalian forms of phospholipase D (PLD), PLD1 and PLD2 (IC50s = 6 and 20 nM, respectively). It dose-dependently decreases the invasive migration of U98-MG glioblastoma cells into matrigel. ML-299 penetrates the central nervous system and is functional in vivo when given intraperitoneally. As PLD1 and PLD2 have roles in cancer and viral infection, ML-299 has potential applications in oncology and virology.
